The biology of cytomegalovirus drug resistance

Current Opinion in Infectious Diseases

Volumn 24, Issue 6, 2011, Pages 605-611

  Hakki, Morgan ^a   Chou, Sunwen ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

Antiviral therapy; Cytomegalovirus; Drug resistance

Indexed keywords

BENZIMIDAVIR; CIDOFOVIR; CIDOFOVIR 3 HEXADECYLOXYPROPYL ESTER; DNA POLYMERASE; FOSCARNET; GANCICLOVIR;

ANTIVIRAL RESISTANCE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DNA POLYMORPHISM; DRUG EXPOSURE; GENE MUTATION; GENE SEQUENCE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PHENOTYPE; REVIEW;

CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, VIRAL; GENOTYPE; HUMANS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); VIRAL PROTEINS;

EID: 80054985564     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32834cfb58     Document Type: Review

References (39)

1. Boeckh M, Geballe AP. Cytomegalovirus: pathogen, paradigm, and puzzle. J Clin Invest 2011; 121:1673-1689.
2. Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89:779-795.
3. Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev 2010; 23:689-712.
4. Prichard MN, Kern ER. The search for new therapies for human cytomegalovirus infections. Virus Res 2011; 157:212-221.
5. Prichard MN. Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir. Rev Med Virol 2009; 19:215-229.
6. Hantz S, Garnier-Geoffroy F, Mazeron MC, et al. Drug-resistant cytomegalovirus in transplant recipients: A French cohort study. J Antimicrob Chemother 2010; 65:2628-2640.
7. Myhre HA, Haug Dorenberg D, Kristiansen KI, et al. Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients. Transplantation 2011; 92:217-223.
8. Van der Beek MT, Berger SP, Vossen AC, et al. Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance. Transplantation 2010; 89:320-326.
9. Iwasenko JM, Scott GM, Naing Z, et al. Diversity of antiviral-resistant human cytomegalovirus in heart and lung transplant recipients. Transpl Infect Dis 2011; 13:145-153.
10. Chou S. Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. Antimicrob Agents Chemother 2010; 54:2371-2378.
11. Martin M, Goyette N, Boivin G. Contrasting effects on ganciclovir susceptibility and replicative capacity of two mutations at codon 466 of the human cytomegalovirus UL97 gene. J Clin Virol 2010; 49:296-298.
12. Martin M, Goyette N, Ives J, Boivin G. Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis. J Clin Virol 2010; 47:321-324.
13. Humar A, Lebranchu Y, Vincenti F, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010; 10:1228-1237.
14. Palmer SM, Limaye AP, Banks M, et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: A randomized, controlled trial. Ann Intern Med 2010; 152:761-769.
15. Chou S, Marousek G, Boivin G, et al. Recombinant phenotyping of cytomegalovirus sequence variants detected after 200 or 100 days of valganciclovir prophylaxis. Transplantation 2010; 90:1409-1413.
16. Schindele B, Apelt L, Hofmann J, et al. Improved detection of mutated human cytomegalovirus UL97 by pyrosequencing. Antimicrob Agents Chemother 2010; 54:5234-5241.
17. Gorzer I, Guelly C, Trajanoski S, Puchhammer-Stockl E. Deep sequencing reveals highly complex dynamics of human cytomegalovirus genotypes in transplant patients over time. J Virol 2010; 84:7195-7203.
18. Posthuma CC, van der Beek MT, van der Blij-de Brouwer CS, et al. Mass spectrometry-based comparative sequencing to detect ganciclovir resistance in the UL97 gene of human cytomegalovirus. J Clin Virol 2011; 51:25-30.
19. Chevillotte M, Ersing I, Mertens T, von Einem J. Differentiation between polymorphisms and resistance associated mutations in the human cytomegalovirus DNA polymerase. Antimicrob Agents Chemother 2010; 54:5004-5011.
20. Chou S. Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. J Clin Virol 2011; 50:287-291.
21. Gilbert C, Azzi A, Goyette N, et al. Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. Antimicrob Agents Chemother 2011; 55:4019-4027.
22. Boutolleau D, Burrel S, Agut H. Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir. Antiviral Res 2011; 91:32-35.
23. Boivin G,Goyette N, Rollag H, et al. Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. Antivir Ther 2009; 14:697-704.
24. Liu S, Knafels JD, Chang JS, et al. Crystal structure of the herpes simplex virus 1 DNA polymerase. J Biol Chem 2006; 281:18193-18200. (Pubitemid 44035619)
25. Lanier R, Trost L, Tippin T, et al. Development of CMX001 for the treatment of poxvirus infections. Viruses 2010; 2:2740-2762.
26. Gentry BG, Kamil JP, Coen DM, et al. Stereoselective phosphorylation of cyclopropavir by pUL97 and competitive inhibition by maribavir. Antimicrob Agents Chemother 2010; 54:3093-3098.
27. Chou S, Bowlin TL. Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility. Antimicrob Agents Chemother 2011; 55:382-384.
28. Shannon-Lowe CD, Emery VC. The effects of maribavir on the autophosphorylation of ganciclovir resistant mutants of the cytomegalovirus UL97 protein. Herpesviridae 2010; 1:4.
29. Chou S, Wechel LC, Marousek GI. Cytomegalovirus UL97 kinase mutations that confer maribavir resistance. J Infect Dis 2007; 196:91-94. (Pubitemid 46982742)
30. Chou S. Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. Antimicrob Agents Chemother 2009; 53:81-85.
31. Reitsma JM, Savaryn JP, Faust K, et al. Antiviral inhibition targeting the HCMV kinase pUL97 requires pUL27-dependent degradation of Tip60 acetyltransferase and cell-cycle arrest. Cell Host Microbe 2011; 9:103-114.
32. Marty FM, Ljungman P, Papanicolaou GA, et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: A phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis 2011; 11:284-292.
33. Snydman DR. Why did maribavir fail in stem-cell transplants? Lancet Infect Dis 2011; 11:255-257.
34. Chou S, Van Wechel LC, Marousek GI. Effect of cell culture conditions on the anticytomegalovirus activity of maribavir. Antimicrob Agents Chemother 2006; 50:2557-2559. (Pubitemid 43993205)
35. Avery RK,Marty FM, Strasfeld L, et al. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. Transpl Infect Dis 2010; 12:489-496.
36. Strasfeld L, Lee I, Villano S, Chou S. Virologic characterization of multidrugresistant cytomegalovirus infection in two transplant recipients treated with maribavir. J Infect Dis 2010; 202:104-108.
37. Lischka P, Hewlett G, Wunberg T, et al. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob Agents Chemother 2010; 54:1290-1297.
38. Goldner T, Hewlett G, Ettischer N, et al. The novel anticytomegalovirus compound AIC246 (letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol 2011; 85:10884-10893.
39. Kaul DR, Stoelben S, Cober E, et al. First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am J Transplant 2011; 11:1079-1084.